We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $159M
1-Year Est. Return 60.94%
This Fund
S&P 500
This Quarter Est. Return
-8.08%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
-$17.6M
Cap. Flow
-$217K
Cap. Flow %
-0.14%
Top 10 Hldgs %
83.26%
Holding
32
New
4
Increased
4
Reduced
–
Closed
8

Top Buys

1
PAGP icon
Plains GP Holdings
PAGP
+$25.2M
2
ABEO icon
Abeona Therapeutics
ABEO
+$6.37M
3
VRCA icon
Verrica Pharmaceuticals
VRCA
+$3.26M
4
ARDX icon
Ardelyx
ARDX
+$2.32M
5
APLT
Applied Therapeutics
APLT
+$2.16M

Top Sells

1
HIGH icon
Simplify Enhanced Income ETF
HIGH
+$28M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$4.47M
3
MBB icon
iShares MBS ETF
MBB
+$2.07M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$1.76M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.63M

Sector Composition

1 Healthcare 79.89%
2 Energy 16.75%
3 Technology 2.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
26
Mirum Pharmaceuticals
MIRM
$7.25B
– –
-70,000
Closed -$1.76M
STRO icon
27
Sutro Biopharma
STRO
$391M
– –
-19,500
Closed -$1.1M
XFOR icon
28
X4 Pharmaceuticals
XFOR
$360M
– –
-17,833
Closed -$744K
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-180,100
Closed -$1.63M
1
2

Similar funds

OS
Objectivity Squared Charleston, South Carolina $159M AUM 22.15% 1-Year Est. Return
BDAM
Blue Door Asset Management Stamford, Connecticut $159M AUM 38.2% 1-Year Est. Return
OC
Oppenheimer & Close New York $159M AUM 60.56% 1-Year Est. Return
JF
Jericho Financial Westerville, Ohio $159M AUM 27.21% 1-Year Est. Return
1L
10Elms LLP Tulsa, Oklahoma $159M AUM 13.16% 1-Year Est. Return
USWIA
UP Strategic Wealth Investment Advisors Pittsburgh, Pennsylvania $159M AUM 24.31% 1-Year Est. Return
RWM
Refined Wealth Management Salt Lake City, Utah $158M AUM 24.38% 1-Year Est. Return
EWA
Elevate Wealth Advisory Athens, Georgia $158M AUM 15.64% 1-Year Est. Return

Propel Bio Management's Q2 2024 Portfolio in Review

As of Q2 2024, Propel Bio Management held 32 positions worth $154M, down 10% from $172M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Propel Bio Management's Q2 2024 filing shows 4 new, 4 increased and 8 closed positions. Its largest new stake was Plains GP Holdings: 1,372,360 shares worth $25.8M. The largest sale was Simplify Enhanced Income ETF, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 79% a quarter earlier, followed by Energy and Technology.

  • Propel Bio Management's largest Q2 2024 buy was Plains GP Holdings: 1,372,360 shares worth $25.8M.
  • Propel Bio Management added most to Ardelyx in Q2 2024, an estimated $2.32M increase.
  • Propel Bio Management fully exited Simplify Enhanced Income ETF in Q2 2024, selling an estimated $28M.
  • Propel Bio Management's ten largest holdings make up 83% of its $154M portfolio in Q2 2024.
  • Propel Bio Management opened 4 new positions and closed 8 in Q2 2024.
  • Propel Bio Management's portfolio value fell 10% quarter-over-quarter to $154M.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.